ClinicalTrials.gg
CompletedNCT00528931Updated Oct 5, 2017Results posted

A Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's Contracture

A Phase 1 interventional study of collagenase clostridium histolyticum in Dupuytren's Contracture, sponsored by Endo Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-05.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing Microbial Collagenase in Dupuytren Contracture — none open to participants now, 1 under way, none of them phase 3. Microbial Collagenase · Dupuytren Contracture.

Enrollment
15th of 17
16 · median 76
Started
2007
with 1 other
Phase 1
Only one
of the 17
Registered
2nd of 17
by date
Lead sponsor
6 of 17
Endo Pharmaceuticals

Among the 17 studies testing Microbial Collagenase in Dupuytren Contracture, this one is the 15th largest by enrollment, is one of 2 that started in 2007, is the only one in phase 1, and was the 2nd registered.

Dupuytren Contracture

78 studies on the registry are indexed under Dupuytren Contracture; 18 are open to participants now.

Browse Dupuytren Contracture studies →

Open to participants now

None of the 17 studies testing Microbial Collagenase in Dupuytren Contracture is open now. The open studies under Dupuytren Contracture, anywhere →

About Microbial Collagenase

Microbial Collagenase: first FDA approval 1965 (SANTYL), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Dupuytren Contracture studies recruiting now, 10 (83%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing Microbial Collagenase in Dupuytren Contracture as a file.
02

Study summary

A Phase 1, open-label, single-dose pharmacokinetic study in subjects with Dupuytren's contracture conducted at one site in the United States. All subjects received a single dose of AA4500 0.58 mg, which was injected directly into the cord affecting either the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint. Pharmacokinetic blood samples were collected before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30. Efficacy and safety assessments were performed up to 30 days after the AA4500 0.58 injection.

This study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 [NCT00528606]and AUX-CC-859 [NCT00533273]) and 7 non-pivotal studies were evaluated.

03

Conditions studied

  • Dupuytren's Contracture

Browse trials for

Keywords

  • Assessment of AUX I and/or AUX II in human plasma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of Dupuytren's contracture, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.
  • Had a positive "table top test," defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.
  • Were naive to AA4500 treatment.
  • Were judged to be in good health.

Exclusion criteria

Exclusion Criteria:

  • Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.
  • Had received treatment for Dupuytren's contracture within 90 days of the AA4500 injection to the MP or PIP selected, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.
  • Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    AA4500 0.58 mg

    Biological: collagenase clostridium histolyticum

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500

    AUX I and AUX II are the constituent protein collagenases of collagenase clostridium histolyticum (AA4500). Plasma concentrations of AUX I and AUX II were assessed through an enzymye-linked-immunoabsorbent assay (ELISA).

    Time frame: Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30

Secondary outcomes

  1. Clinical Success

    Clinical success defined as a reduction in contracture (ie, flexion deformity) to ≤5° of normal as measured by finger goniometry 30 days after an injection. Last observation carried forward (LOCF) after the injection was used if the status at day 30 could not be determined.

    Time frame: 30 days after treatment to the primary joint

  2. Clinical Improvement

    Clinical improvement defined as ≥50% reduction from baseline in contracture within 30 days of the injection. LOCF after the injection was used if the status at day 30 could not be determined.

    Time frame: 30 days after treatment to the primary joint

  3. Percent Change From Baseline Contracture

    Change from baseline in the degree of fixed-flexion contracture calculated as 100 times (baseline contracture minus last available post-injection contracture measurement) divided by baseline contracture where a positive change indicates a reduction in the degree of contracture.

    Time frame: Baseline, 30 days after treatment to the primary joint

  4. Change From Baseline Range of Motion

    Range of motion defined as the difference between the finger extension angle and finger flexion angle expressed in degrees

    Time frame: Baseline, 30 days after treatment to the primary joint

07

Results

Posted Aug 20, 2012

Participant flow

Participant flow — Overall Study
MilestoneAA4500 0.58 mg
Started16
Completed15
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500

AUX I and AUX II are the constituent protein collagenases of collagenase clostridium histolyticum (AA4500). Plasma concentrations of AUX I and AUX II were assessed through an enzymye-linked-immunoabsorbent assay (ELISA).

Time frame:
Before dosing, at predetermined time points through the 24 hours after dosing, Day 7, and Day 30
Reported as:
Number · participants
Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500
participantsAA4500 0.58 mg
Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA45000
SecondaryClinical Success

Clinical success defined as a reduction in contracture (ie, flexion deformity) to ≤5° of normal as measured by finger goniometry 30 days after an injection. Last observation carried forward (LOCF) after the injection was used if the status at day 30 could not be determined.

Time frame:
30 days after treatment to the primary joint
Reported as:
Number · Percentage of joints
Clinical Success
Percentage of jointsAA4500 0.58 mg
Clinical Success75.0
SecondaryClinical Improvement

Clinical improvement defined as ≥50% reduction from baseline in contracture within 30 days of the injection. LOCF after the injection was used if the status at day 30 could not be determined.

Time frame:
30 days after treatment to the primary joint
Reported as:
Number · Percentage of joints
Clinical Improvement
Percentage of jointsAA4500 0.58 mg
Clinical Improvement100.0
SecondaryPercent Change From Baseline Contracture

Change from baseline in the degree of fixed-flexion contracture calculated as 100 times (baseline contracture minus last available post-injection contracture measurement) divided by baseline contracture where a positive change indicates a reduction in the degree of contracture.

Time frame:
Baseline, 30 days after treatment to the primary joint
Reported as:
Mean · Percentage of contracture change
Percent Change From Baseline Contracture
Percentage of contracture changeAA4500 0.58 mg
Percent Change From Baseline Contracture91.6 ± 16.57
SecondaryChange From Baseline Range of Motion

Range of motion defined as the difference between the finger extension angle and finger flexion angle expressed in degrees

Time frame:
Baseline, 30 days after treatment to the primary joint
Reported as:
Mean · Degrees
Change From Baseline Range of Motion
DegreesAA4500 0.58 mg
Change From Baseline Range of Motion39.1 ± 15.38

Adverse events

Collected over From the time that the first dose of study drug was administered until 30 days elapsed following discontinuation of study drug administration.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AA4500 0.58 mg—1/16 (6.3%)16/16 (100%)
Most frequent serious events
Most frequent serious events
EventAA4500 0.58 mg
Tendon ruptureInjury, poisoning and procedural complications1/16
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAA4500 0.58 mg
Injection site haemorrhageGeneral disorders15/16
Injection site swellingGeneral disorders14/16
Injection site painGeneral disorders13/16
HypertensionVascular disorders2/16
ParaesthesiaNervous system disorders2/16
BlisterSkin and subcutaneous tissue disorders1/16
Blood urine presentInvestigations1/16
Burning sensationNervous system disorders1/16
ContusionInjury, poisoning and procedural complications1/16
Food poisoningGastrointestinal disorders1/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AA4500 0.58 mg
<=18 years0
Between 18 and 65 years12
>=65 years4
Age, Continuous
Age, Continuous(years)AA4500 0.58 mg
Mean60.6 ± 11.74
Sex: Female, Male
Sex: Female, Male(Participants)AA4500 0.58 mg
Female1
Male15
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)AA4500 0.58 mg
Black or African American1
White14
Other1
Region of Enrollment
Region of Enrollment(participants)AA4500 0.58 mg
United States16
08

Study locations

1 site
  • Providence Clinical Research
    Burbank, California 91505, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Dec 2007 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 4 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2007
First posted
Sep 12, 2007
Start
Sep 2007
Primary completionActual
Dec 2007
CompletionActual
Mar 2008
Results first posted
Aug 20, 2012
Last update
Oct 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00528931
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Sep 2007
Primary completion
Dec 2007
Completion
Mar 2008
Results posted
Aug 20, 2012
Last update
Oct 5, 2017

Study contacts

Veronica Urdaneta, MD
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion